The report provides a detailed analysis essential for establishing a Riluzole production plant. It encompasses all critical aspects necessary for Riluzole production, including the cost of Riluzole production, Riluzole plant cost, Riluzole production costs, and the overall Riluzole production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Riluzole production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Riluzole is used for treating amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). It extends survival by slowing disease progression in early-stage patients, delaying the need for ventilators or tracheostomy. It exerts neuroprotective effects by modulating glutamatergic neurotransmission and blocking presynaptic glutamate release.
It stops persistent sodium and calcium currents, enhancing astrocyte glutamate uptake, and providing antioxidative protection against excitotoxicity and oxidative stress in motor neurons. It is also used in other motor neuron diseases (o-MND), spinal cord injury for neuroprotection, psychiatric conditions like anxiety, OCD, and depression via glutamate modulation. It is also utilised in Parkinson's, Huntington's, epilepsy, and even oncology through antiproliferative effects.
The Riluzole market is driven by the global prevalence of amyotrophic lateral sclerosis. The ageing populations worldwide, along with enhanced diagnostic capabilities that catch cases earlier fuels its market. The greater public and medical awareness leads to higher diagnosis rates, and expanded healthcare access in developing regions further contributes to its market growth.
The industrial Riluzole procurement is influenced by complex production requirements demanding adherence to good production practices. Also, detailed drug master files, certificates of analysis, and strict purity standards to guarantee batch consistency impact its sourcing costs. The volume-based pricing support and pilot batch assistance, while emphasising long-term supplier partnerships affects its usage as a first-line therapy in managing ALS progression.
Raw Material for Riluzole Production
According to the Riluzole production plant project report, the key raw materials used in the production of Riluzole include 4-(Trifluoromethoxy)Aniline, Potassium Thiocyanate, and Bromine.
Production Process of Riluzole
The extensive Riluzole production cost report consists of the following major industrial production process:
- From 4-(Trifluoromethoxy)Aniline: The production process of Riluzole starts with the addition of potassium thiocyanate to a solution of 4-(trifluoromethoxy)aniline in glacial acetic acid. The mixture is stirred at room temperature before cooling just enough to maintain liquidity. Now, a solution of bromine in glacial acetic acid is added dropwise, and the reaction is allowed to warm to room temperature and stirred overnight. The mixture is diluted with water, alkalised and extracted, and the combined organic layers are dried over, filtered, and concentrated under reduced pressure, to get Riluzole as the final product.
Riluzole appears as a white to slightly yellow or off-white crystalline powder. It has a molecular formula of C8H5F3N2OS and a molecular weight of 234.20 g/mol. It has a melting point of 116-118 degree Celsius and has a predicted boiling point of 296.3 degree Celsius. It has a density of 1.572 g/cm³ and is very soluble in dimethylformamide, dimethylsulfoxide, and methanol. It is freely soluble in dichloromethane, sparingly soluble in HCl, and soluble in DMSO. It has a logP around 2.28-2.96, indicating moderate lipophilicity and a pKa of 2.96. It has a benzothiazole core with a trifluoromethoxy group at position 6 and an amino group at 2, and it supports one hydrogen bond donor, three acceptors, two rotatable bonds, and a topological polar surface area of 45-76 Ų.
